Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
11/2000
11/16/2000WO2000068223A1 Ureas and their use as cell adhesion modulators
11/16/2000WO2000068215A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/16/2000WO2000068213A1 Substituted bicyclic compounds
11/16/2000WO2000068208A1 Pyrimidinones derivatives for the treatment of atherosclerosis
11/16/2000WO2000068206A1 Heterocyclically substituted benzimidazoles, the production and application thereof
11/16/2000WO2000068198A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/16/2000WO2000068195A2 Substituted pyrrolidines as cell adhesion inhibitors
11/16/2000WO2000068188A1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors
11/16/2000WO2000067796A1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/16/2000WO2000067777A1 A method of prophylaxis and treatment and agents useful therefor
11/16/2000WO2000067776A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
11/16/2000WO2000067769A1 Enhanced survival of cancer patients treated with erythropoietin and antitumor agents
11/16/2000WO2000067767A1 Poplar bud extract and its combination with squalane as anti-inflammatory medicine
11/16/2000WO2000067761A1 Compositions and methods for identifying antigens which elicit an immune response
11/16/2000WO2000067759A1 Novel, specific inhibitors of acute and chronic inflammation
11/16/2000WO2000067752A1 Use of succinic acid derivatives to obtain a medicine for treating inflammation
11/16/2000WO2000067746A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
11/16/2000WO2000067734A2 Use of phthalazine derivatives
11/16/2000WO2000067626A2 Oat extracts: refining, compositions and methods of use
11/16/2000WO2000053633A3 Antibody and chemokine constructs that are directed to ccr5, and their use for treating autoimmune diseases
11/16/2000WO2000053228A3 Use of niaouli essential oil as transdermal permeation enhancer
11/16/2000WO2000048996A3 β-ALANINE DERIVATIVES
11/16/2000WO2000042179A3 Complex-forming proteins
11/16/2000WO2000042168A3 Bifidobacterium in the treatment of inflammatory disease
11/16/2000WO2000041669A3 Benzimidazole vascular damaging agents
11/16/2000WO2000041469A3 β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS
11/16/2000WO2000037639A3 Lymphocytic membrane proteins
11/16/2000WO2000037059A3 Compositions and methods to inactivate n-type calcium channels
11/16/2000WO2000037025A3 Antibodies to truncated vegf-d and uses thereof
11/16/2000WO2000034468A3 Muc-1 antagonists and methods of treating immune disorders
11/16/2000WO2000024907A3 Library of novel "unnatural" natural products
11/16/2000WO2000022439A3 Method and substances for diagnosis and therapy of sepsis and sepsis-like systemic infections
11/16/2000WO2000018365A3 Fast dissolving orally consumable films
11/16/2000WO2000005375A9 Gbs toxin receptor
11/16/2000DE19922407A1 Preparing medicament for treating viral infections, liver diseases or cancer, comprising recombinant parapoxvirus targeted towards specific organs, cells or tissues
11/16/2000DE19921567A1 Verwendung von Phthalazine-Derivaten Use of derivatives phthalazines
11/16/2000DE19920247A1 Arzneimittel mit einem Gehalt an Verbindungen mit einem Stickstoff-Sauerstoff-Heterocyclus als Wirkstoff und ihre Verwendung Medicaments with an amount of compounds having a nitrogen-oxygen heterocycle as active ingredient and their use
11/16/2000DE19919149A1 Von Interferon alpha-2 abgeleitete Peptid-Homodimere und Peptid-Heterodimere Of interferon alpha-2 derived peptide homodimers and peptide heterodimers
11/16/2000CA2388092A1 Stereoselective antifibrillogenic peptides and peptidomimetics thereof
11/16/2000CA2374237A1 Compositions and methods for identifying antigens which elicit an immune response
11/16/2000CA2373759A1 Serine proteases
11/16/2000CA2373443A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
11/16/2000CA2373079A1 Substituted benzolactam compounds
11/16/2000CA2373052A1 Novel, specific inhibitors of acute and chronic inflammation
11/16/2000CA2373015A1 Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
11/16/2000CA2372815A1 Extracellular matrix and adhesion-associated proteins
11/16/2000CA2372782A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
11/16/2000CA2372704A1 Use of phthalazine derivatives
11/16/2000CA2369333A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/16/2000CA2369323A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/15/2000EP1052285A2 Method of inducing an antigen-specific anticytotoxic cell
11/15/2000EP1052255A1 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics.
11/15/2000EP1052254A1 Nitrogenous heterocyclic derivatives and medicine thereof
11/15/2000EP1051993A2 5HT1 receptor agonists and either a cox-2 inhibitor or NSAID for the treatment of migraine
11/15/2000EP1051972A1 Nitric oxide donor composition and method for treatment of anal disorders
11/15/2000EP1051511A1 Methods of identifying modulators of kinases responsive to stress
11/15/2000EP1051431A1 Thrombin inhibitors
11/15/2000EP1051428A1 Human cystatin f
11/15/2000EP1051425A2 2-(PURIN-9-yl)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES
11/15/2000EP1051407A1 2,3,4,5-tetrahydro-1h-[1,4]-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
11/15/2000EP1051405A2 Novel dihydroxyhexanoic acid derivatives
11/15/2000EP1051399A1 Phenylalanine derivatives useful as pharmaceutical agents
11/15/2000EP1051395A1 Hydroxamic and carboxylic acid derivatives
11/15/2000EP1051192A2 Methods for the prevention and treatment of fibrosis and sclerosis
11/15/2000EP1051150A1 Anti-enzyme compositions comprising ethylenediamine disuccinic acid
11/15/2000CN1273532A Bovine excretion extracts having anticancer and anti-inflammatory activity and process for preparing the same
11/15/2000CN1273529A Vitronection receptor antagonist
11/15/2000CN1273527A Taste masked pharmaceutical compositions
11/15/2000CN1273125A Chinese medicine containing ant for treating rheumatism and its preparing process
11/15/2000CN1273124A Powder prepared with colophony, realgar and 'Huangdan'
11/15/2000CN1273102A Oral liquid for treating rheumatic and rheumatoid arthritides
11/15/2000CN1273101A Thermal picking for recovery of hyperosteogeny and protrusion of intervertebral disc
11/15/2000CN1058499C 16-substituted-4-aza-androstane 5-alpha-reductase isoazyne 1 inhibitors
11/15/2000CN1058494C New diosmetin compound, process for their preparation and pharmaceutial compositions containing them
11/15/2000CN1058398C Chinese medicine for treatment of gynecopathy and preparation method thereof
11/14/2000US6147250 Treating diseases mediated by vascular cell adhesion molecule-1, including cardiovascular and inflammatory diseases; succinobucol
11/14/2000US6147223 Lactacystin analogs
11/14/2000US6147212 Proline-naphthylalanine dipeptide amidated with an acyl derivative on the n-terminus and a 4-phenyl-1-piperazinyl derivative on the carboxyl terminus; neurokinin (tachykinin) antagonist
11/14/2000US6147188 Irreversible cathepsin or calpain inhibitors
11/14/2000US6147100 Antiinflammatory agents
11/14/2000US6147096 Substituted pyrrolobenzimidazoles for treating inflammatory diseases
11/14/2000US6147080 Inhibitors of p38
11/14/2000US6147061 Antiarthritic agents; anticancer agents; oral diseases
11/14/2000US6147050 5-lipoxygenase-activating protein II
11/14/2000US6146876 22025, a novel human cyclic nucleotide phosphodiesterase
11/14/2000US6146845 Polynucleotides encoding a sialoadhesin family member-2 (SAF-2)
11/14/2000US6146625 Deactivating pathological amounts of platelet-activating factor in mammal by administering a culture product protein
11/14/2000CA2308323A1 5ht1 receptor agonists and either a cox-2 inhibitor or nsaid for the treatment of migraine
11/14/2000CA2000763C Dispersable formulation
11/09/2000WO2000066737A1 VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY
11/09/2000WO2000066631A1 SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?
11/09/2000WO2000066630A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS
11/09/2000WO2000066622A1 T20/dp178 and t21/dp107 are activators of human phagocyte formyl peptide receptors
11/09/2000WO2000066618A1 Integrin receptor antagonists
11/09/2000WO2000066611A1 Steroid derivatives
11/09/2000WO2000066586A1 Heteroaryl diazabicycloalkanes, their preparation and use
11/09/2000WO2000066572A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
11/09/2000WO2000066567A1 Pyrimidinone compounds
11/09/2000WO2000066566A1 Pyrimidine compounds
11/09/2000WO2000066562A1 Pyrazoles having antiinflammatory activity
1 ... 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 ... 1272